BJU Int

1. MEHAWED G, Murray R, Rukin NJ, Roberts MJ, et al
   Prostate tumour visualisation with PET: is image fusion with MRI the answer?
   BJU Int. 2024;133 Suppl 4:4-6.
   

   >> Share

   
   
2. STATTIN P, Fleming S, Lin X, Lefresne F, et al
   Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
   BJU Int. 2024 Apr 15. doi: 10.1111/bju.16362.
   

   >> Share

   
   
3. RODRIGUEZ-SANCHEZ L, Reiter R, Rodriguez A, Emberton M, et al
   The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer.
   BJU Int. 2024 Apr 13. doi: 10.1111/bju.16360.
   

   >> Share

   
   

   
   BMC Cancer

4. LIU HE, Vuppalapaty M, Hoerner CR, Bergstrom CP, et al
   Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate c
   BMC Cancer. 2024;24:482.
   

   >> Share

   
   
5. YOU X, Qiu J, Li Q, Zhang Q, et al
   Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.
   BMC Cancer. 2024;24:472.
   

   >> Share

   
   

   
   BMC Urol

6. HE Y, Fan Y, Song H, Shen Q, et al
   A novel biopsy scheme for prostate cancer: targeted and regional systematic biopsy.
   BMC Urol. 2024;24:85.
   

   >> Share

   
   

   
   Cancer Res

7. CUNNINGHAM M, Schiewer MJ
   PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.
   Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-3458.
   

   >> Share

   
   

   
   Clin Cancer Res

8. ARCHER S, Brailey PM, Song M, Bartlett PD, et al
   CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
   Clin Cancer Res. 2024;30:1595-1606.
   

   >> Share

   
   

   
   Eur J Radiol

9. PAUSCH AM, Elsner C, Rupp NJ, Eberli D, et al
   MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score.
   Eur J Radiol. 2024;175:111463.
   

   >> Share

   
   

   
   Eur Urol

10. CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
11. GRABBERT M, Liakos N, Gratzke C
    Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
    Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
12. LIGHT A, Mayor N, Cullen E, Kirkham A, et al
    The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
    Eur Urol. 2024;85:466-482.
    

    >> Share

    
    
13. ANAND M, Jain B, Aggarwal S
    Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
    Eur Urol. 2024;85:e145.
    

    >> Share

    
    
14. HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al
    Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
    Eur Urol. 2024;85:e146-e147.
    

    >> Share

    
    

    
    Hum Pathol

15. WISSING M, Brimo F, McKercher G, Scarlata E, et al
    Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada.
    Hum Pathol. 2024 Apr 10:S0046-8177(24)00054.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

16. ROY S, Malone S, Sun Y, Zaorsky NG, et al
    Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase 3 Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2024;119:119-126.
    

    >> Share

    
    
17. SUN Y, Tsai Y, Wood R, Shen B, et al
    KDM3B Single-Nucleotide Polymorphisms Impact Radiation Therapy Toxicity Through Circular RNA-Mediated KDM3B Expression and Inflammatory Responses.
    Int J Radiat Oncol Biol Phys. 2024;119:251-260.
    

    >> Share

    
    
18. ALEXANDER A, Gagne I, Bahl G, Kim D, et al
    Late Toxicity of Prostate Ultrahypofractionated Radiation Therapy Compared With Moderate Hypofractionation in a Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2024;119:110-118.
    

    >> Share

    
    

    
    Int J Urol

19. BLAS L, Shiota M, Tanegashima T, Tsukahara S, et al
    Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
    Int J Urol. 2024;31:404-408.
    

    >> Share

    
    

    
    J Clin Oncol

20. 
    Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2024 Apr 16:JCO2400454. doi: 10.1200/JCO.24.00454.
    

    >> Share

    
    

    
    J Nucl Med

21. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    

    >> Share

    
    
22. HUANG YY, Lin TC, Yang SH, Lai LS, et al
    [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
    J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533.
    

    >> Share

    
    

    
    Lancet Oncol

23. HOUEDE N, Hebert K
    Combining enzalutamide and [(177)Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
    Lancet Oncol. 2024 Apr 12:S1470-2045(24)00179.
    

    >> Share

    
    
24. EMMETT L, Subramaniam S, Crumbaker M, Nguyen A, et al
    [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2024 Apr 12:S1470-2045(24)00135.
    

    >> Share

    
    

    
    Nat Rev Urol

25. CAO PHA, Dominic A, Lujan FE, Senthilkumar S, et al
    Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.
    Nat Rev Urol. 2024 Apr 16. doi: 10.1038/s41585-024-00869.
    

    >> Share

    
    

    
    Oncogene

26. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031.
    

    >> Share

    
    

    
    Oncol Rep

27. PARAJULI KR, Jung Y, Taichman RS
    Abscisic acid signaling through LANCL2 and PPARgamma induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
    Oncol Rep. 2024;51:39.
    

    >> Share

    
    
28. LIU Y, Qin Z, Yang K, Liu R, et al
    [Corrigendum] Cripto?1 promotes epithelial?mesenchymal transition in prostate cancer via Wnt/beta?catenin signaling.
    Oncol Rep. 2024;51:75.
    

    >> Share

    
    

    
    PLoS Genet

29. TIMMINS IR, Dudbridge F
    Bayesian approach to assessing population differences in genetic risk of disease with application to prostate cancer.
    PLoS Genet. 2024;20:e1011212.
    

    >> Share

    
    

    
    Prostate

30. GRINDEDAL EM, Zucknick M, Stormorken A, Ronne E, et al
    Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24711.
    

    >> Share

    
    
31. BERG FM, Correia ETO, Abenojar EC, Basilion JP, et al
    Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease.
    Prostate. 2024;84:682-693.
    

    >> Share

    
    
32. SIMANEK V, Vrzakova R, Vitak R, Jirasko M, et al
    Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
    Prostate. 2024;84:656-665.
    

    >> Share

    
    
33. KOSTECKA LG, Mendez S, Li M, Khare P, et al
    Cancer cells employ lipid droplets to survive toxic stress.
    Prostate. 2024;84:644-655.
    

    >> Share

    
    
34. ZHAO F, Zhao J, Wei X, Shi Y, et al
    Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24710.
    

    >> Share

    
    
35. JIA T, Liu C, Guo P, Xu Y, et al
    FOXA1 regulates ribosomal RNA transcription in prostate cancer.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24714.
    

    >> Share

    
    

    
    Urology

36. SAWYER MD, Kim FJ, Wiesen B, Lloyd GL, et al
    Novel Prostate Biopsy Technique Using Imaging Fusion in a Patient With Absent Rectum.
    Urology. 2024;185:124-130.
    

    >> Share

    
    
37. TOURINHO-BARBOSA R, Sanchez-Salas R, Sivaraman A, Borges RC, et al
    Urinary Symptoms Change and Quality of Life After Robotic Radical Prostatectomy: A Secondary Analysis of a Randomized Controlled Trial.
    Urology. 2024;185:73-79.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share